Elonox
Enoxaparin sodium biosimilar developed by Fresenius Kabi. Reference product Clexane (Lovenox in the United States).
Brands by market: Elonox (Canada) · Commercial partner or holder: Fresenius Kabi · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCOct 2022approved
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About Elonox
Elonox is Fresenius Kabi's enoxaparin for Canada, approved in October 2022, with a higher-strength form.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada · Elonox
Health CanadaApprovedBrand
Elonox
Holder or applicant
Fresenius Kabi Canada LTD
Pathway
Biosimilar biologic drug (Notice of Compliance)
Approved
Oct 2022
Application or permission
DIN 02532247, 02532255, 02532263, 02532271, 02532298, 02532301, 02532328
Presentations
100, 30, 40, 60, 80 mg; 120, 150 mg
Remarks
Also Elonox Hp.
Source
S022 (Health Canada) · checked Sep 2026
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Elonox holds an approval, these are the other enoxaparin sodium biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| HC | 4 | Baxter (Axberi), Juno Pharma Canada (Noromby), Sandoz (Inclunox), Techdow (Inhixa) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Fresenius Kabi: Conexxence / Bomyntra, Idacio, Stimufend, Tyenne.
Chronology
- HCOct 2022Notice of Compliance, Health Canada
Sources
Planning enoxaparin sodium biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.